EDITORIAL
Tissue plasminogen activator
Tissue plasminogen activator therapy for the eye
University of South Carolina School of Medicine, Columbia, SC, USA
Correspondence to:
Correspondence to:
Professor Ramesh C Tripathi
Department of Ophthalmology, Vision Research Laboratories, 6439 Garners Ferry Road, Columbia, SC 29209, USA; tripathi@med.sc.edu
Past, present, and future
Keywords: tissue plasminogen activator
| The first 150 words of the full text of this article appear below. |
The systemic (intravenous) administration of genetically modified (recombinant) tissue plasminogen activator (tPA) for thrombolysis in coronary arteries was approved by the US Federal Drug Administration in 1988. Since then, use of this approved drug has been extended to many non-approved indications, especially in the eye.1
Tissue plasminogen activator is a naturally occurring serine protease produced by a variety of mammalian tissues, especially endothelial cells. Ocular tissues that contain tPA include the conjunctiva, cornea, trabecular meshwork, lens, vitreous, and retina.1–3 In normal adult human eyes, the aqueous humour contains a significant amount of tPA that is some 30 times more than in plasma.4 The major enzymatic action of tPA is the conversion of plasminogen (a zymogen) into plasmin, an active serine protease that hydrolyses fibrin. Compared to other fibrinolytic agents (for example, urokinase and streptokinase), tPA has several advantages: fibrin forms a ternary complex with tPA and plasminogen,
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Relevant Article
- Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery
- H Siatiri, A H Beheshtnezhad, H Asghari, N Siatirit, S Moghimi, and N Piri
Br. J. Ophthalmol. 2005 89: 1458-1461.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
-
Lei, H., Velez, G., Hovland, P., Hirose, T., Kazlauskas, A.
(2008). Plasmin Is the Major Protease Responsible for Processing PDGF-C in the Vitreous of Patients with Proliferative Vitreoretinopathy. IOVS
49: 42-48
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Paediatrics
-
Ophthalmologic surgical procedures
-
Angle
-
Eye (globe)
-
Intraocular pressure
- Relevant Article
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
